“We believe the addition of this clinically differentiated technology to our vascular portfolio demonstrates our continued commitment to provide meaningful innovation for physicians who care for patients with peripheral vascular disease,” Jennings added.
Boston Scientific $1.16B Silk Road Deal : Closing and Approvals
Silk Road announced in a separate statement that the transaction is expected to close in the second half of 2024. The company’s board has unanimously approved the deal and recommends shareholder approval. Upon closing, Silk Road will become a wholly owned subsidiary of Boston Scientific.
Advisory Teams
Fried Frank is advising BofA Securities, the exclusive financial adviser to Silk Road, with a team that includes partners Philip Richter and Roy Tannenbaum. The Latham team representing Boston Scientific is led by corporate partners Julie Scallen and Ian Nussbaum, with support from benefits and compensation partner Josh Friedman, tax partner Nicholas J. DeNovio, life sciences regulatory partners Betty Pang and Elizabeth Richards, and data privacy partner Heather Deixler. Deal team information for the Wilson Sonsini Goodrich & Rosati PC team representing Silk Road was not immediately available.
